Iran Pharmaceuticals and Healthcare Report Q1 2009

  • ID: 682765
  • January 2009
  • Region: Iran
  • 72 Pages
  • Business Monitor International
1 of 4

This Iran Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Iran's pharmaceuticals and healthcare industry.

While pharmaceutical spending levels have risen steadily in recent years, Iran’s pharmaceutical market remains in development stages. Access to basic healthcare is widespread, with up to 90% of the rural population and almost the entire urban population having adequate public healthcare coverage. The authorities are also active in terms of prevention, in the past five years spending around US$20mn on HIV/AIDS control and education, with a focus on drug users.

In December 2008, Iran Daily reported that a representative of the United Nations Children’s Fund (UNICEF) stated that AIDS is in Iran limited to ‘high-risk ‘groups, which confirms that the authorities are addressing key sectors of society. The use of locally produced generics is widespread, especially in the government healthcare sector, with the domestic industry meeting up to 95% of pharmaceutical demand in the country. In October 2008, the minister of health and medical education, Mohammad Baqer Baqeri-Lankarani, stated that the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary 5
SWOT Analysis 6
Table: Iran Pharmaceuticals And Healthcare Industry SWOT 6
Iran Political SWOT 7
Iran Economic SWOT 7
Iran Business Environment SWOT 8
Business Environment Ranking 9
Table: Middle East And Africa Pharmaceutical Business Environment Ratings 9
Limits Of Potential Returns 10
Risks To Realisation Of Returns 10
Iran – Market Summary 12
Registration Of Imports 14
Generic Registration 14
Intellectual Property (IP) Regime 15
Intellectual Property Disputes 15
Counterfeit Medicines 16
Pricing And Reimbursement 17
Recent Pricing And Reimbursement Developments 17
Industry Developments 19
Epidemiology 19
HIV/AIDS Situation 19
Table: Iran HIV/AIDS Prevalence 20
Healthcare Sector 21
Primary Care 22
Secondary Care 22
Health Insurance 23
Regional Developments 23
International Healthcare Collaboration 24
Pharmaceutical Industry 24
Traditional Herbal Remedies 26
Recent Company Activity 26
Retail Pharmacies 27
Research And Development 27
International Pharmaceutical Collaboration 28
Industry Forecast Scenario 30
Overall Market Forecast 30
Table: Iran – Drug Expenditure Forecasts, 2003-2013 (IRRmn unless otherwise stated) 31
Key Growth Factors – Industry 31
Table: Iran – Health Expenditure Forecasts, 2003-2013 (IRRmn unless otherwise stated) 32
Key Growth Factors – Macroeconomic 33
Table: Iran – Economic Activity 35
Prescription Market Forecast 36
Table: Iran – Prescription Drug Market Forecast, 2003-2013 (US$mn unless otherwise stated) 37
OTC Market Forecast 38
Table: Iran – OTC Market Data Forecasts, 2003-2013 (US$mn unless otherwise stated) 39
Patented Market Forecast 40
Table: Iran – Patented Market Forecasts, 2003-2013 (IRRmn unless otherwise stated) 40
Generics Market Forecast 41
Table: Iran – Generics Market Forecasts, 2003-2013 (IRRmn unless otherwise stated) 41
Medical Device Market Forecast 42
Table: Iran – Medical Device Market Forecast, 2006-2013 (US$mn unless otherwise stated) 44
Import/Export Market Forecast 45
Table: Iran – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) 46
Other Healthcare Data Forecasts 47
Table: Iran – Other Health Indicators, 2003-2013 47
Key Risks To BMI’s Forecast Scenario 48
Competitive Landscape 49
Company Profiles 50
Multinationals 50
Novartis 50
Merck & Co 50
Pfizer 50
GlaxoSmithKline 50
Sanofi-Aventis 50
Indigenous Companies 51
Darou Pakhsh 51
Caspian Tamin Pharmaceutical Company* 53
Pharmieco 55
Pars Darou 56
Zahravi 58
Amin 60
Sina Darou Pharmaceutical Company 61
Exir Pharmaceuticals 63
Country Snapshot: Iran Demographic Data 64
Section 1: Population 64
Source: UN Population Division 64
Table: Demographic Indicators, 2005-2030 64
Table: Rural/Urban Breakdown, 2005-2030 65
Section 2: Education And Healthcare 65
Table: Education, 2002-2005 65
Table: Vital Statistics, 2005-2030 65
Section 3: Labour Market And Spending Power 66
Table: Employment Indicators, 1996-2005 66
Table: Consumer Expenditure, 2000-2012 (US$) 67
Table: Average Annual Manufacturing Wages, 2000-2012 67
BMI Forecast Modelling 68
How We Generate Our Pharmaceutical Industry Forecasts 68
Pharmaceutical Business Environment Ratings Methodology 68
Ratings Overview 69
Table: Pharmaceutical Business Environment Indicators 69
Weighting 70
Table: Weighting Of Components 70

Note: Product cover images may vary from those shown
3 of 4

Novartis, Merck & Co, Pfizer, GlaxoSmithKline, Sanofi-Aventis, Darou Pakhsh, Caspian Tamin Pharmaceutical Company, Pharmieco, Pars Darou, Zahravi, Amin

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.